ERBB2 KD mutants do not bind osimertinib

Stable Identifier
R-HSA-9665280
Type
Reaction [transition]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

The following ERBB2 KD mutants are resistant to osmertinib:
ERBB2 T798I (Hanker et al. 2017);
ERBB2 T798M (Hanker et al. 2017);
ERBB2 L869R (Hanker et al. 2017);

Literature References
PubMed ID Title Journal Year
28274957 An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer

Hanker, AB, Brewer, MR, Sheehan, JH, Koch, JP, Sliwoski, GR, Nagy, R, Lanman, R, Berger, MF, Hyman, DM, Solit, DB, He, J, Miller, V, Cutler, RE, Lalani, AS, Cross, D, Lovly, CM, Meiler, J, Arteaga, CL

Cancer Discov 2017
Participants
Participates
Normal reaction
Functional status

Loss of function of ERBB2 KD mutants (osimertinib resistant):ERBIN:HSP90:CDC37 [plasma membrane]

Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!